Leo Pharma gets FDA psoriasis treatment approval

Leo Pharma and Warner Chilcott have received approval from the US Food and Drug Administration (FDA) for the psoriasis treatment Taclonex (Dovobet).

The New Drug Application (NDA) for Taclonex was submitted to the FDA in March 2005 as a treatment for of psoriasis vulgaris in adults. The ointment contains a combination of calcipotriene 0.005 per cent and betamethasone dipropionate 0.064 per cent.

Warner Chilcott CEO Roger Boissonneault said: “Taclonex presents an exciting proposition for the treatment of psoriasis in the U.S., and we are preparing for its launch with great anticipation.”

Warner Chilcott is the exclusive licensee of Taclonex in the US and the company expects to launch the drug in the first half of this year.

Psoriasis, which has no cure, affects around 2 per cent of the UK population and the condition involves the overproduction of skin cells.

© Adfero Ltd